{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:47:35Z","timestamp":1790754455302,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015236","name":"Lupin Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015236","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.acvd.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:54:22Z","timestamp":1713196462000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy"],"prefix":"10.1016","volume":"117","author":[{"given":"Karim","family":"Wahbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bassez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josselin","family":"Duchateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savine","family":"Vicart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-4401","authenticated-orcid":false,"given":"Fabien","family":"Labombarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-7425","authenticated-orcid":false,"given":"Jean-Marc","family":"Sellal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Deharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2024.03.001_bib0225","series-title":"Myotonic dystrophy","author":"Harper","year":"2001"},{"key":"10.1016\/j.acvd.2024.03.001_bib0230","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of Statewide Blood Screening Program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.acvd.2024.03.001_bib0235","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/mus.26420","article-title":"The myotonic dystrophy experience: a North American cross-sectional study","volume":"59","author":"Hagerman","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.acvd.2024.03.001_bib0240","series-title":"GeneReviews\u00ae","article-title":"Myotonia congenita","author":"Dun\u00f8","year":"1993"},{"key":"10.1016\/j.acvd.2024.03.001_bib0245","doi-asserted-by":"crossref","first-page":"e014006","DOI":"10.1161\/JAHA.119.014006","article-title":"Clinical care recommendations for cardiologists treating adults with myotonic dystrophy","volume":"9","author":"McNally","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2024.03.001_bib0250","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.03.001_bib0255","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.acvd.2024.03.001_bib0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/CPJ.0000000000000645","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 2","volume":"9","author":"Schoser","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.acvd.2024.03.001_bib0265","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.hrthm.2022.04.022","article-title":"2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders","volume":"19","author":"Groh","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.acvd.2024.03.001_bib0270","doi-asserted-by":"crossref","first-page":"103489","DOI":"10.1016\/j.drudis.2023.103489","article-title":"The myotonic dystrophy type 1 drug development pipeline: 2022 edition","volume":"28","author":"Pascual-Gilabert","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.acvd.2024.03.001_bib0275","first-page":"665","article-title":"[Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine]","volume":"139","author":"Pouget","year":"1983","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.acvd.2024.03.001_bib0280","series-title":"Les antiarythmiques. Pr\u00e9cis de rythmologie","first-page":"71","author":"Wilkin","year":"2022"},{"key":"10.1016\/j.acvd.2024.03.001_bib0285","unstructured":"Lupin Europe GmbH. NaMuscla summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/namuscla-epar-product-information_en.pdf [accessed 17 August 2023]."},{"key":"10.1016\/j.acvd.2024.03.001_bib0290","unstructured":"Haute Autorit\u00e9 de sant\u00e9 (HAS). NAMUSCLA (mexil\u00e9tine). https:\/\/www.has-sante.fr\/jcms\/p_3246176\/fr\/namuscla-mexiletine [accessed 19 January 2023]."},{"key":"10.1016\/j.acvd.2024.03.001_bib0295","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.1546326","article-title":"An unstable triplet repeat in a gene related to myotonic muscular dystrophy","volume":"255","author":"Fu","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.acvd.2024.03.001_bib0300","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.1062125","article-title":"Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9","volume":"293","author":"Liquori","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.acvd.2024.03.001_bib0305","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/355548a0","article-title":"Cloning of the essential myotonic dystrophy region and mapping of the putative defect","volume":"355","author":"Aslanidis","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2024.03.001_bib0310","doi-asserted-by":"crossref","first-page":"e0148264","DOI":"10.1371\/journal.pone.0148264","article-title":"Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study","volume":"11","author":"Dogan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2024.03.001_bib0315","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification","volume":"172","author":"De Antonio","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.acvd.2024.03.001_bib0320","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.acvd.2024.03.001_bib0325","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.nmd.2011.04.009","article-title":"A new window on neurocognitive dysfunction in the childhood form of myotonic dystrophy type 1 (DM1)","volume":"21","author":"Angeard","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.acvd.2024.03.001_bib0330","doi-asserted-by":"crossref","first-page":"10491","DOI":"10.3390\/ijms231810491","article-title":"Development of therapeutic approaches for myotonic dystrophies type 1 and type 2","volume":"23","author":"Timchenko","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.acvd.2024.03.001_bib0335","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.acvd.2024.03.001_bib0340","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1056\/NEJMoa062800","article-title":"Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1","volume":"358","author":"Groh","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.03.001_bib0345","first-page":"751","article-title":"Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1","volume":"38","author":"Wahbi","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.03.001_bib0350","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijcard.2015.03.069","article-title":"Myotonic dystrophy and the heart: a systematic review of evaluation and management","volume":"184","author":"Lau","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2024.03.001_bib0355","first-page":"222","article-title":"Myotonic dystrophy type 2: the 2020 update","volume":"39","author":"Meola","year":"2020","journal-title":"Acta Myol"},{"key":"10.1016\/j.acvd.2024.03.001_bib0360","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.ijcard.2012.11.076","article-title":"The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes","volume":"168","author":"Sansone","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2024.03.001_bib0365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJM198701013160106","article-title":"Mexiletine","volume":"316","author":"Campbell","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.03.001_bib0370","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/europace\/euac087","article-title":"Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review","volume":"24","author":"van der Ree","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2024.03.001_bib0375","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/CIRCRESAHA.118.314050","article-title":"Predicting patient response to the antiarrhythmic mexiletine based on genetic variation","volume":"124","author":"Zhu","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2024.03.001_bib0380","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.03.001_bib0385","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.82.4.1106","article-title":"Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials","volume":"82","author":"Coplen","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.03.001_bib0390","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JND-200582","article-title":"Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine","volume":"8","author":"Desaphy","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.acvd.2024.03.001_bib0395","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.hrthm.2020.05.043","article-title":"Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up","volume":"17","author":"Vio","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.acvd.2024.03.001_bib0400","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fneur.2020.00300","article-title":"Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias","volume":"11","author":"Modoni","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.acvd.2024.03.001_bib0405","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.acvd.2024.03.001_bib0410","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.03.001_bib0415","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2024.03.001_bib0420","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.acvd.2024.03.001_bib0425","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.acvd.2024.03.001_bib0430","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/WNL.0000000000011002","article-title":"Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial","volume":"96","author":"Heatwole","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.acvd.2024.03.001_bib0435","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1212\/CPJ.0000000000001073","article-title":"Long-term safety and efficacy of mexiletine in myotonic dystrophy types 1 and 2","volume":"11","author":"Mousele","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.acvd.2024.03.001_bib0440","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.recesp.2021.04.002","article-title":"Cardiovascular effects of mexiletine for treatment of myotonia in myotonic dystrophy type 1","volume":"74","author":"Salguero-Bodes","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213624000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213624000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T13:33:19Z","timestamp":1718371999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213624000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":44,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1875213624000597"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2024.03.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}